COMP <GO>
NEPH vs LLY // EV/EBITDA & P/E VALUATION
Nephros Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NEPH 3
— LLY 9
▲ EV/EBITDA & P/E VALUATION LEADER: NEPH
LAST: $3.27 (+3.16%) • MKT CAP: $35.5M
valuation
26.3x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEPH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEPH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.90% | 83.64% | -21.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 32.36% | -13.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 26.3x | 36.4x | -10.12 | NEPH | /valuation <GO> |
| Free Cash Flow Yield | 4.50% | 2.30% | +2.20 | NEPH | /fcf-yield <GO> |
| Operating Margin | 6.10% | 40.21% | -34.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 6.40% | 31.90% | -25.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 32.70% | 45.51% | -12.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 66.6 | -29.92 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 26.3x | -1.25 | NEPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.5M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEPH REV | LLY REV | NEPH GROSS % | LLY GROSS % | NEPH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $18.8M | $65.18B | 61.9% | 83.0% | $1.6M | $16.81B |
| FY 2024 | $14.2M | $45.04B | 61.6% | 81.3% | -$547.0K | $8.82B |
| FY 2023 | $14.2M | $34.12B | — | 79.3% | $827.0K | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEPH // BETA —
LLY // BETA 0.51